Buscar
Connect Biopharma Holdings Ltd
CNTBAñadir a la lista de seguimiento
2.460USD
+0.070+2.93%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
154.27MCap. mercado
PérdidaP/E TTM
Más Datos de Connect Biopharma Holdings Ltd Compañía
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Información de Connect Biopharma Holdings Ltd
Símbolo de cotizaciónCNTB
Nombre de la empresaConnect Biopharma Holdings Ltd
Fecha de salida a bolsaMar 19, 2021
Director ejecutivoQuart (Barry D)
Número de empleados62
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 19
Dirección3580 Carmel Mountain Road, Suite 200
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Teléfono18587271040
Sitio Webhttps://www.connectbiopharm.com
Símbolo de cotizaciónCNTB
Fecha de salida a bolsaMar 19, 2021
Director ejecutivoQuart (Barry D)
Ejecutivos de Connect Biopharma Holdings Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Mr. James Z. Huang
Mr. James Z. Huang
Independent Director
Independent Director
--
--
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Director
Director
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Connect Biopharma Holdings Ltd?
Los cinco principales accionistas de Connect Biopharma Holdings Ltd son: Dr. Barry D. Quart, Pharm.D.
¿Cuántas instituciones poseen acciones de Connect Biopharma Holdings Ltd (CNTB)?
A fecha de 2026Q1, 51 instituciones poseen acciones de Connect Biopharma Holdings Ltd, con un valor de mercado combinado de aproximadamente 29.94M, lo que representa el 52.97% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 8109973.00.